A polyprodrug-based nanoplatform for cisplatin prodrug delivery and combination cancer therapy

Chem Commun (Camb). 2019 Nov 19;55(93):13987-13990. doi: 10.1039/c9cc06567a.

Abstract

Polyprodrug-based delivery technique is a fast-growing and effective strategy to improve the therapeutic efficacy of small molecule drugs. We herein developed a robust mitoxantrone (MTO)-based polyprodrug nanoplatform for systemic cisplatin prodrug delivery and combination cancer therapy. Our results show that this nanoplatform can concurrently transport MTO and cisplatin to tumor cells and significantly inhibit tumor growth.

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cisplatin / chemistry
  • Cisplatin / pharmacology*
  • Combined Modality Therapy
  • Drug Delivery Systems*
  • Drug Screening Assays, Antitumor
  • Humans
  • Mitoxantrone / chemistry
  • Mitoxantrone / pharmacology*
  • Nanoparticles / chemistry*
  • Neoplasms, Experimental / drug therapy
  • Neoplasms, Experimental / metabolism
  • Neoplasms, Experimental / pathology
  • Optical Imaging
  • Particle Size
  • Polymers / chemistry
  • Polymers / pharmacology*
  • Prodrugs / chemistry
  • Prodrugs / pharmacology*
  • Reactive Oxygen Species / analysis
  • Reactive Oxygen Species / metabolism

Substances

  • Antineoplastic Agents
  • Polymers
  • Prodrugs
  • Reactive Oxygen Species
  • Mitoxantrone
  • Cisplatin